ImmunoPET: concept, design, and applications
W Wei, ZT Rosenkrans, J Liu, G Huang, QY Luo… - Chemical …, 2020 - ACS Publications
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …
[HTML][HTML] Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade
G Crișan, NS Moldovean-Cioroianu… - International Journal of …, 2022 - mdpi.com
Positron emission tomography (PET) uses radioactive tracers and enables the functional
imaging of several metabolic processes, blood flow measurements, regional chemical …
imaging of several metabolic processes, blood flow measurements, regional chemical …
Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with …
J Violet, P Jackson, J Ferdinandus… - Journal of Nuclear …, 2019 - Soc Nuclear Med
177Lu-prostate-specific membrane antigen (PSMA)–617 enables targeted delivery of β-
particle radiation to prostate cancer. We determined its radiation dosimetry and relationships …
particle radiation to prostate cancer. We determined its radiation dosimetry and relationships …
Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding
C Kratochwil, F Bruchertseifer, H Rathke… - Journal of Nuclear …, 2017 - Soc Nuclear Med
The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation
therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with …
therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with …
First-in-humans imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion …
N Pandit-Taskar, MA Postow… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Immunotherapy is becoming the mainstay for treatment of a variety of malignancies, but only
a subset of patients responds to treatment. Tumor-infiltrating CD8-positive (CD8+) T …
a subset of patients responds to treatment. Tumor-infiltrating CD8-positive (CD8+) T …
CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: a phase I first-in-humans study of 89Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody
There is a need for in vivo diagnostic imaging probes that can noninvasively measure tumor-
infiltrating CD8+ leukocytes. Such imaging probes could be used to predict early response …
infiltrating CD8+ leukocytes. Such imaging probes could be used to predict early response …
PSMA theranostics: current status and future directions
K Rahbar, A Afshar-Oromieh, H Jadvar… - Molecular …, 2018 - journals.sagepub.com
Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics
and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases …
and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases …
A perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies
DS O'Keefe, DJ Bacich, SS Huang… - Journal of Nuclear …, 2018 - Soc Nuclear Med
In this review, we cover the evolution of knowledge on the biology of prostate-specific
membrane antigen (PSMA) and its translation to therapy. The usual key to discovery is a …
membrane antigen (PSMA) and its translation to therapy. The usual key to discovery is a …
[HTML][HTML] Current Perspectives on 89Zr-PET Imaging
JK Yoon, BN Park, EK Ryu, YS An, SJ Lee - International Journal of …, 2020 - mdpi.com
89Zr is an emerging radionuclide that plays an essential role in immuno-positron emission
tomography (PET) imaging. The long half-life of 89Zr (t1/2= 3.3 days) is favorable for …
tomography (PET) imaging. The long half-life of 89Zr (t1/2= 3.3 days) is favorable for …
Design and challenges of radiopharmaceuticals
K Vermeulen, M Vandamme, G Bormans… - Seminars in nuclear …, 2019 - Elsevier
This review describes general concepts with regard to radiopharmaceuticals for diagnostic
or therapeutic applications that help to understand the specific challenges encountered …
or therapeutic applications that help to understand the specific challenges encountered …